{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:06Z","timestamp":1761630786557},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/tp.0000000000001611","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T19:50:34Z","timestamp":1492890634000},"page":"933-937","source":"Crossref","is-referenced-by-count":15,"title":["Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C"],"prefix":"10.1097","volume":"101","author":[{"given":"Elliot B.","family":"Tapper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nezam H.","family":"Afdhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-12-20210211","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-12-20210211","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R4-12-20210211","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R5-12-20210211","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"R6-12-20210211","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"key":"R7-12-20210211","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient\u2010reported outcomes: results from the ION\u20101,\u20102, and\u20103 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"R8-12-20210211","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"The Lancet"},{"key":"R9-12-20210211","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"key":"R10-12-20210211","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1572-0241.2001.03537.x","article-title":"Assessment of utilities and health-related quality of life in patients with chronic liver disease","volume":"96","author":"Younossi","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R11-12-20210211","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"R12-12-20210211","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"R13-12-20210211","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R14-12-20210211","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.gastro.2015.01.011","article-title":"The changing liver transplant waitlist: an emerging liver purgatory?","volume":"3","author":"Asrani","year":"2015","journal-title":"Gastroenterology"},{"key":"R15-12-20210211","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"R16-12-20210211","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2016.06.023","article-title":"Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma","volume":"65","author":"Yang","year":"2016","journal-title":"J Hepatol"},{"key":"R17-12-20210211","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-12-20210211","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"R19-12-20210211","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon \u03b1-2b plus ribavirin versus interferon \u03b1-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"key":"R20-12-20210211","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","article-title":"Estimation of utilities for chronic hepatitis C from SF-36 scores","volume":"100","author":"Thein","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R21-12-20210211","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.12880","article-title":"Patients' preferences and health utility assessment with SF\u20106D and EQ\u20105D in patients with chronic hepatitis C treated with sofosbuvir regimens","volume":"40","author":"Stepanova","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R22-12-20210211","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2015.241","article-title":"Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography","volume":"110","author":"Tapper","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R23-12-20210211","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40273-015-0373-9","article-title":"Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals","volume":"34","author":"Chhatwal","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"R24-12-20210211","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"Chhatwal","year":"2015","journal-title":"Ann Intern Med"},{"key":"R25-12-20210211","first-page":"73","article-title":"Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population.","volume":"65-","author":"Chahal","year":"2016","journal-title":"JAMA Intern Med"},{"key":"R26-12-20210211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"J Hepatol"},{"key":"R27-12-20210211","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/apt.13081","article-title":"Cost\u2010effectiveness of all\u2010oral ledipasvir\/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-12-20210211","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection","volume":"162","author":"Linas","year":"2015","journal-title":"Ann Intern Med"},{"key":"R29-12-20210211","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.13320","article-title":"Cost\u2010effectiveness of new direct\u2010acting antivirals to prevent post\u2013liver transplant recurrent hepatitis","volume":"15","author":"Cortesi","year":"2015","journal-title":"Am J Transplant"},{"key":"R30-12-20210211","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/liv.13033","article-title":"Cost-effectiveness of ombitasvir\/paritaprevir\/ritonavir, dasabuvir + ribavirin for US post-liver transplant recurrent genotype 1 HCV","volume":"36","author":"Saab","year":"2016","journal-title":"Liver Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:27:09Z","timestamp":1620977229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201705000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001611","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}